NVS - Diabetes patients facing insurance hurdles getting GLP-1s: report
2023-12-12 14:34:38 ET
More on Eli Lilly, Novartis, etc.
- Novartis: Post Investor Day, Higher Guidance Priced In
- Bubble Warning: Unrealistic Growth Priced In And Multiple Risk Factors For Eli Lilly
- Eli Lilly and Company (LLY) Presents at 6th Evercore ISI HealthCONx Conference (Transcript)
- Eli Lilly presents updated data on cancer medication
- Eli Lilly slips as weight loss drug's effect reverses after therapy
For further details see:
Diabetes patients facing insurance hurdles getting GLP-1s: report